From: Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study
N = 30
N = 90
Rate
Width
95% CI
0.1
0.22
0.04–0.26
0.13
0.05–0.18
0.2
0.28
0.10–0.37
0.16
0.13–0.29
0.3
0.31
0.17–0.48
0.19
0.22–0.40